Seattle Genetics Overview
- Founded
- 1997

- Status
- Public
- Employees
- 1,605

- Stock Symbol
- SGEN

- Investments
- 4
- Share Price
- $190.80
- (As of Wednesday Closing)
Seattle Genetics General Information
Description
Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.
Contact Information
- 30th Drive Southeast
- Suite 21823
- Bothell, WA 98021
- United States
Seattle Genetics Stock Performance
(As of Wednesday Closing)
Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
---|---|---|---|---|---|---|
$190.80 | $188.78 | $90.57 - $213.94 | $34.2B | 179M | 940K | $2.73 |
Seattle Genetics Financials Summary
In Thousands, USD |
TTM 30-Sep-2020 | FY 2019 31-Dec-2019 | FY 2018 31-Dec-2018 | FY 2017 31-Dec-2017 |
---|---|---|---|---|
EV | 33,217,394 | 18,790,185 | 8,610,790 | 7,243,062 |
Revenue | 1,864,047 | 916,713 | 654,700 | 482,250 |
EBITDA | 528,713 | (125,136) | (220,314) | (134,618) |
Net Income | 472,405 | (158,650) | (222,693) | (125,530) |
Total Assets | 3,004,961 | 2,205,866 | 1,503,329 | 877,949 |
Total Debt | 65,003 | 77,052 | 0 |
Seattle Genetics Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
This information is available in the PitchBook Platform. To explore Seattle Genetics‘s full profile, request access.
Request a free trialSeattle Genetics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
---|
This information is available in the PitchBook Platform. To explore Seattle Genetics‘s full profile, request access.
Request a free trialSeattle Genetics Comparisons
Industry
00000000
00000
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialSeattle Genetics Competitors (50)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Exelixis | Formerly VC-backed | Alameda, CA | 000 | 00000 | 0&0 | |
00000 | Formerly VC-backed | Cambridge, MA | 000 | 00000 | 000000&0 | |
000000 | Formerly VC-backed | Monrovia, CA | 000 | 00000 | 00000000 | 00000 |
000000 00000000000 | Formerly VC-backed | San Francisco, CA | 000 | 00.000 | 000000000 | 00.000 |
000000000 | Formerly VC-backed | Waltham, MA | 00 | 00000 | 00000000 | 00000 |
Seattle Genetics Executive Team (13)
Seattle Genetics Board Members (11)
Name | Representing | Role | Since |
---|---|---|---|
Clay Siegall Ph.D | Seattle Genetics | Co-Founder, President, Chief Executive Officer & Chairman of the Board | 000 0000 |
Daniel Welch | Self | Board Member | 000 0000 |
David Gryska | Self | Board Member | 000 0000 |
Felix Baker Ph.D | Baker Bros. Advisors | Board Member | 000 0000 |
John Orwin | Self | Board Member | 000 0000 |
Seattle Genetics Signals
Growth Rate

Growth

Size Multiple


Key Data Points
Twitter Followers
5.5k

Similarweb Unique Visitors
15.0K

Majestic Referring Domains
314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialSeattle Genetics Investments & Acquisitions (4)
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
000000000 00000000 | 01-Mar-2018 | 000000000000000000 | 00000 | Biotechnology | 0000 0000000 00.0 |
0000000-00000 0000 | 01-Oct-2017 | 000000000 00000 00 | 000.00 | Buildings and Property | 0000 0000000 00.0 |
00000 00000 000000 | 01-Aug-2017 | 000000000000000000 | 000.00 | Laboratory Services (Healthcare) | 000000 00000 00.0 |
Cogent Biosciences | 11-Jun-2015 | Early Stage VC | 0000 | Biotechnology | 0000 0000000 00.0 |
Seattle Genetics Exits (1)
Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
---|---|---|---|---|---|
000000 00000000000 | 11-Jun-2015 | 00000 00000 00 | 0000 | Completed |
|